147 related articles for article (PubMed ID: 23703438)
1. Molecular modeling, structural analysis and identification of ligand binding sites of trypanothione reductase from Leishmania mexicana.
Mutlu O
J Vector Borne Dis; 2013 Mar; 50(1):38-44. PubMed ID: 23703438
[TBL] [Abstract][Full Text] [Related]
2.
Matadamas-Martínez F; Hernández-Campos A; Téllez-Valencia A; Vázquez-Raygoza A; Comparán-Alarcón S; Yépez-Mulia L; Castillo R
Molecules; 2019 Sep; 24(18):. PubMed ID: 31487860
[TBL] [Abstract][Full Text] [Related]
3. Cloning and expression of trypanothione reductase from a New World Leishmania species.
Castro-Pinto DB; Genestra M; Menezes GB; Waghabi M; Gonçalves A; De Nigris Del Cistia C; Sant'Anna CM; Leon LL; Mendonça-Lima L
Arch Microbiol; 2008 Apr; 189(4):375-84. PubMed ID: 18060667
[TBL] [Abstract][Full Text] [Related]
4. Homology modeling, docking and molecular dynamics of the Leishmania mexicana arginase: a description of the catalytic site useful for drug design.
Méndez-Cuesta CA; Méndez-Lucio O; Castillo R
J Mol Graph Model; 2012 Sep; 38():50-9. PubMed ID: 23085157
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking studies of selected tricyclic and quinone derivatives on trypanothione reductase of Leishmania infantum.
Venkatesan SK; Shukla AK; Dubey VK
J Comput Chem; 2010 Oct; 31(13):2463-75. PubMed ID: 20340105
[TBL] [Abstract][Full Text] [Related]
6. Modeled structure of trypanothione reductase of Leishmania infantum.
Singh BK; Sarkar N; Jagannadham MV; Dubey VK
BMB Rep; 2008 Jun; 41(6):444-7. PubMed ID: 18593527
[TBL] [Abstract][Full Text] [Related]
7. Homology modeling of T. cruzi and L. major NADH-dependent fumarate reductases: ligand docking, molecular dynamics validation, and insights on their binding modes.
Merlino A; Vieites M; Gambino D; Coitiño EL
J Mol Graph Model; 2014 Mar; 48():47-59. PubMed ID: 24370672
[TBL] [Abstract][Full Text] [Related]
8. Novel aryl β-aminocarbonyl derivatives as inhibitors of Trypanosoma cruzi trypanothione reductase: binding mode revised by docking and GRIND2-based 3D-QSAR procedures.
de Paula da Silva CH; Bernardes LS; da Silva VB; Zani CL; Carvalho I
J Biomol Struct Dyn; 2012; 29(6):702-16. PubMed ID: 22546000
[TBL] [Abstract][Full Text] [Related]
9. Binding to large enzyme pockets: small-molecule inhibitors of trypanothione reductase.
Persch E; Bryson S; Todoroff NK; Eberle C; Thelemann J; Dirdjaja N; Kaiser M; Weber M; Derbani H; Brun R; Schneider G; Pai EF; Krauth-Siegel RL; Diederich F
ChemMedChem; 2014 Aug; 9(8):1880-91. PubMed ID: 24788386
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the trypanothione metabolism.
Colotti G; Saccoliti F; Gramiccia M; Di Muccio T; Prakash J; Yadav S; Dubey VK; Vistoli G; Battista T; Mocci S; Fiorillo A; Bibi A; Madia VN; Messore A; Costi R; Di Santo R; Ilari A
Amino Acids; 2020 Feb; 52(2):247-259. PubMed ID: 31037461
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of antimony treatment in leishmaniasis.
Baiocco P; Colotti G; Franceschini S; Ilari A
J Med Chem; 2009 Apr; 52(8):2603-12. PubMed ID: 19317451
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of Trypanosoma brucei trypanothione reductase: comparative molecular field analysis modeling and structural basis for selective inhibition.
Ferreira LG; Andricopulo AD
Future Med Chem; 2013 Oct; 5(15):1753-62. PubMed ID: 24144411
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs.
Colotti G; Baiocco P; Fiorillo A; Boffi A; Poser E; Chiaro FD; Ilari A
Future Med Chem; 2013 Oct; 5(15):1861-75. PubMed ID: 24144416
[TBL] [Abstract][Full Text] [Related]
14. The structure of Trypanosoma cruzi trypanothione reductase in the oxidized and NADPH reduced state.
Lantwin CB; Schlichting I; Kabsch W; Pai EF; Krauth-Siegel RL
Proteins; 1994 Feb; 18(2):161-73. PubMed ID: 8159665
[TBL] [Abstract][Full Text] [Related]
15. Probing the dimerization interface of Leishmania infantum trypanothione reductase with site-directed mutagenesis and short peptides.
Toro MA; Sánchez-Murcia PA; Moreno D; Ruiz-Santaquiteria M; Alzate JF; Negri A; Camarasa MJ; Gago F; Velázquez S; Jiménez-Ruiz A
Chembiochem; 2013 Jul; 14(10):1212-7. PubMed ID: 23744811
[TBL] [Abstract][Full Text] [Related]
16. Leishmania infantum trypanothione reductase is a promiscuous enzyme carrying an NADPH:O2 oxidoreductase activity shared by glutathione reductase.
Angiulli G; Lantella A; Forte E; Angelucci F; Colotti G; Ilari A; Malatesta F
Biochim Biophys Acta; 2015 Sep; 1850(9):1891-7. PubMed ID: 26033467
[TBL] [Abstract][Full Text] [Related]
17. A potential target enzyme for trypanocidal drugs revealed by the crystal structure of NAD-dependent glycerol-3-phosphate dehydrogenase from Leishmania mexicana.
Suresh S; Turley S; Opperdoes FR; Michels PA; Hol WG
Structure; 2000 May; 8(5):541-52. PubMed ID: 10801498
[TBL] [Abstract][Full Text] [Related]
18. Insights about resveratrol analogs against trypanothione reductase of
da Silva AD; Dos Santos JA; Machado PA; Alves LA; Laque LC; de Souza VC; Coimbra ES; Capriles PVSZ
J Biomol Struct Dyn; 2019 Jul; 37(11):2960-2969. PubMed ID: 30058445
[TBL] [Abstract][Full Text] [Related]
19. Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity.
Stoll VS; Simpson SJ; Krauth-Siegel RL; Walsh CT; Pai EF
Biochemistry; 1997 May; 36(21):6437-47. PubMed ID: 9174360
[TBL] [Abstract][Full Text] [Related]
20. Identification and binding mode of a novel Leishmania Trypanothione reductase inhibitor from high throughput screening.
Turcano L; Torrente E; Missineo A; Andreini M; Gramiccia M; Di Muccio T; Genovese I; Fiorillo A; Harper S; Bresciani A; Colotti G; Ilari A
PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006969. PubMed ID: 30475811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
